Corticoliberin, somatocrinin and amine contents in normal and parkinsonian human hypothalamus.
We have compared hypothalamic contents of various neurotransmitters (dopamine (DA), norepinephrine and serotonin) and their metabolites (dihydroxyphenyl acetic acid, homovanilic acid, 5-hydroxyindoleacetic acid) in post-mortem human controls and parkinsonian hypothalami. Neurotransmitters and their metabolites were measured in 0.1 N HCl hypothalami extracts using electrochemical detection after high performance liquid chromatography. Using specific radioimmunoassays we have also measured corticoliberin and somatocrinin contents in these hypothalami. Despite a 50% decrease of DA contents in parkinsonian hypothalami, no variations of corticoliberin and somatocrinin contents were found: 16.6 +/- 1.78 pg/mg tissue in Parkinson disease vs 16.71 +/- 1.89 in controls for human corticotropin-releasing factor (hCRF 1-41) and 37.38 +/- 11 vs 45.16 for human growth-hormone-releasing factor (hGRF 1-44).
B
B
Conte-Devolx
M
M
Grino
A
A
Nieoullon
F
F
Javoy-Agid
E
E
Castanas
V
V
Guillaume
M C
MC
Tonon
H
H
Vaudry
C
C
Oliver
D015102:3,4-Dihydroxyphenylacetic Acid / Q000032:analysis; D000368:Aged; D001679:Biogenic Amines / Q000032:analysis*; D003346:Corticotropin-Releasing Hormone / Q000032:analysis*; D004298:Dopamine / Q000032:analysis; D005260:Female; D013007:Growth Hormone-Releasing Hormone / Q000032:analysis*; D006719:Homovanillic Acid / Q000032:analysis; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000032:analysis; D007031:Hypothalamus / Q000032:analysis*; D008297:Male; D010300:Parkinson Disease / Q000378:metabolism*; D010446:Peptide Fragments / Q000032:analysis*; D012701:Serotonin / Q000032:analysis
D001679:Biogenic Amines; D010446:Peptide Fragments; D015102:3,4-Dihydroxyphenylacetic Acid; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D003346:Corticotropin-Releasing Hormone; D013007:Growth Hormone-Releasing Hormone; D004298:Dopamine; D006719:Homovanillic Acid